BB Biotech AG (BB.XMIL) Financials
All currency values in CHF millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | CHF 809 | CHF 587 | CHF 82 | -CHF 200 | -CHF 351 | -CHF 396 |
| Income Tax Expense | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 0 |
| Net Income | ||||||
| Net Income | CHF 798 | CHF 578 | CHF 76 | -CHF 207 | -CHF 358 | -CHF 405 |
| Per Share Data | ||||||
| Revenue Per Share | CHF 14.67 | CHF 10.70 | CHF 1.50 | -CHF 3.64 | -CHF 6.76 | -CHF 7.58 |
| EPS (Basic) | CHF 14.56 | CHF 10.54 | CHF 1.38 | -CHF 3.77 | -CHF 6.50 | -CHF 7.31 |
| EPS (Diluted) | CHF 14.56 | CHF 10.54 | CHF 1.38 | -CHF 3.77 | -CHF 6.50 | -CHF 7.31 |
| Shares Outstanding | 55.1M | 54.8M | 54.8M | 54.8M | 51.9M | 52.3M |
| Dividends Per Share | CHF 2.25 | CHF 1.80 | CHF 2.00 | CHF 2.85 | CHF 4.09 | CHF 3.82 |
BB Biotech (BB.XMIL) financials: revenue, profit and margins
BB Biotech (BB.XMIL) generated about CHF 809 million in revenue and CHF 798 million in net income (a 98.6% net margin) over the trailing twelve months, growing at roughly 613.1% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is BB Biotech's (BB.XMIL) revenue?+
BB Biotech generated about CHF 809 million in revenue over the trailing twelve months. Revenue has grown at roughly 613.1% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is BB Biotech profitable?+
Yes, BB Biotech reported about CHF 798 million in net income over the trailing twelve months, a net profit margin of roughly 98.6%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are BB Biotech's profit margins?+
BB Biotech runs a net margin of about 98.6%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is BB Biotech growing?+
BB Biotech's revenue has compounded at roughly 613.1% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside BB.XMIL's margins and free cash flow. This is analysis from company filings, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BB.XMIL
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.